Aisling Capital is an investment firm focused on health-related innovations, particularly in biotechnology and biopharmaceuticals. The firm typically invests in Series A to Series E rounds, with a strong emphasis on later-stage investments such as Series B and Series C. Aisling Capital targets companies developing novel therapeutics for disease diagnosis, prevention, and treatment, leveraging advancements in genomics and biotechnology.
Notable portfolio companies include BridgeBio Pharma, Biohaven Pharmaceuticals, and Loxo Oncology. Key partners at Aisling Capital bring extensive experience from leading institutions in the healthcare sector. The firm's investment philosophy centers on backing transformative healthcare innovations with the potential to address significant unmet medical needs. Aisling Capital offers value-add services such as strategic guidance, operational support, and access to a robust network of industry experts to help portfolio companies achieve their growth objectives.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.
Top Investment Stages
A2 Biotherapeutics

Genesys Capital
genesyscapital.com

Aquilo Capital Management
aquilocap.com

Ally Bridge Group
ally-bridge.com

Alpha Square Group

Biospring Partners
biospring.com
Axil Capital
axilcapital.com

Aphelion Capital

Avalon BioVentures

Soleus Capital
soleuscapital.com

Vivo Capital
vivocapital.com

Altitude Life Science Ventures
altitudelsv.com

Biomatics Capital Partners

ALS Investment Fund

Align Capital
aligncapital.com

A* Capital
a-star.co

Solas BioVentures
solasbio.com
Bioeconomy Capital

Targeted Technology Fund
targetedtech.com
Avalon Ventures

Apposite Capital